TransMedics Group, Inc. (TMDX) shareholders
Close on Nov 17, 2026Market cap $3.26BP/E 24.4Yield 0.00%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Abigail P. Johnson Joint filing with FMR LLC (15.00%) | 5,058,396 | 15.00% | 13G (passive) amendment | Mar 31, 2025 |
| BlackRock, Inc. | 4,955,262 | 14.60% | 13G (passive) amendment | Jun 30, 2025 |
| Vanguard Portfolio Management | 1,949,420 | 5.68% | 13G (passive) | Mar 31, 2026 |
| Vanguard Capital Management | 1,737,137 | 5.06% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TMDX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 5,596,549 | 16.14% | $371.72M | +303,218 | 0.01% |
| FMR LLC | 5,133,328 | 14.80% | $340.96M | +37,085 | 0.01% |
| Vanguard Portfolio Management LLC | 1,933,989 | 5.58% | $128.46M | +14,454 | 0.01% |
| Vanguard Capital Management LLC | 1,497,600 | 4.32% | $99.47M | +19,448 | 0.00% |
| State Street Corp | 1,420,421 | 4.10% | $94.34M | +100,942 | 0.00% |
| Nomura Asset Management International Inc. | 910,495 | 2.63% | $60.48M | +24,654 | 0.09% |
| Geode Capital Management, LLC | 894,913 | 2.58% | $59.45M | +55,758 | 0.00% |
| Hood River Capital Management LLC | 751,133 | 2.17% | $49.89M | +51,363 | 0.36% |
| Dimensional Fund Advisors LP | 610,107 | 1.76% | $40.53M | +93,428 | 0.01% |
| Braidwell LP | 609,715 | 1.76% | $40.50M | +280,324 | 1.50% |
| Goldman Sachs Group Inc | 559,771 | 1.61% | $37.18M | −306,511 | 0.00% |
| Citadel Advisors LLC | 558,824 | 1.61% | $37.12M | +497,223 | 0.00% |
| Eventide Asset Management, LLC | 548,874 | 1.58% | $36.46M | +50 | 0.49% |
| Wellington Management Group Llp | 515,973 | 1.49% | $34.27M | +29,500 | 0.01% |
| Emerald Advisers, LLC | 490,491 | 1.41% | $32.58M | +147,700 | 0.77% |
| UBS Group AG | 488,058 | 1.41% | $32.42M | −92,735 | 0.00% |
| Morgan Stanley | 405,112 | 1.17% | $26.91M | −289,038 | 0.00% |
| UBS Asset Management Americas Inc | 398,250 | 1.15% | $26.45M | −541,273 | 0.00% |
| Invesco Ltd. | 394,979 | 1.14% | $26.23M | −642,995 | 0.00% |
| Citigroup Inc | 386,066 | 1.11% | $25.64M | +28,685 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 374 | 35M | 100.0% | 68 / 140 | 123 / 106 | 4M | 6M |
| Q1 2026 | 416 | 37M | 100.0% | 67 / 149 | 137 / 71 | 7M | 4M |
| Q4 2025 | 429 | 37M | 100.0% | 90 / 156 | 127 / 45 | 4M | 4M |
| Q3 2025 | 388 | 38M | 100.0% | 75 / 153 | 119 / 51 | 5M | 4M |
| Q2 2025 | 368 | 37M | 100.0% | 104 / 116 | 114 / 32 | 4M | 6M |
| Q1 2025 | 299 | 39M | 100.0% | 52 / 122 | 90 / 64 | 8M | 8M |
| Q4 2024 | 315 | 39M | 100.0% | 74 / 130 | 85 / 125 | 11M | 9M |
| Q3 2024 | 374 | 37M | 100.0% | 77 / 135 | 123 / 41 | 11M | 6M |
| Q2 2024 | 340 | 35M | 99.9% | 107 / 97 | 116 / 27 | 6M | 6M |
| Q1 2024 | 262 | 35M | 100.0% | 51 / 93 | 81 / 34 | 4M | 5M |
| Q4 2023 | 248 | 37M | 100.0% | 49 / 81 | 89 / 21 | 5M | 4M |
| Q3 2023 | 221 | 36M | 100.0% | 34 / 96 | 67 / 52 | 7M | 6M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
331 funds held TMDX in Q2 2026, 47% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of TMDX | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 2,082,539 | 6.01% | $138.32M | 0.12% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,038,890 | 3.00% | $69.00M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 891,470 | 2.57% | $59.21M | 0.07% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 752,168 | 2.17% | $49.96M | 0.03% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund | 726,130 | 2.09% | $55.56M | 0.63% | Jul 31, 2026 |
| Nomura Small Cap Core Fund | 617,377 | 1.78% | $41.49M | 0.75% | May 29, 2026 |
| Fidelity Advisor New Insights Fund | 614,300 | 1.77% | $40.80M | 0.14% | Jun 30, 2026 |
| VIP Contrafund Portfolio | 589,600 | 1.70% | $39.16M | 0.13% | Jun 30, 2026 |
| Eventide Gilead Fund | 460,684 | 1.33% | $30.60M | 0.89% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 434,956 | 1.25% | $28.89M | 0.06% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 397,504 | 1.15% | $26.40M | 0.03% | Jun 30, 2026 |
| VIP Mid Cap Portfolio | 383,700 | 1.11% | $25.49M | 0.27% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 375,096 | 1.08% | $28.70M | 0.08% | Jul 31, 2026 |
| SMALLCAP World Fund Inc | 374,177 | 1.08% | $24.85M | 0.03% | Jun 30, 2026 |
| Fidelity Small Cap Growth K6 Fund | 370,081 | 1.07% | $28.31M | 0.62% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Waleed H. Hassanein | President & CEO, Director | 666,102 | 1.92% | Jul 14, 2026 |
| Fernando N. Araujo | See Remarks | 22,969 | 0.07% | Oct 30, 2026 |
| Nicholas Corcoran | See remarks | 41,558 | 0.12% | Jul 14, 2026 |
| Gerardo Hernandez | Chief Financial Officer | 31,935 | 0.09% | Jul 14, 2026 |
| Matthew S. Forsyth | See Remarks | 15,409 | 0.04% | May 21, 2026 |
| Anil P. Ranganath | See remarks | 13,091 | 0.04% | Mar 4, 2026 |
| Giovanni Cecere | Chief Commercial Officer | 7,975 | 0.02% | Feb 20, 2026 |
| Tamer I. Khayal | Chief Commercial Officer | 36,042 | 0.10% | Mar 5, 2025 |
| James R. Tobin | Director | 158,068 | 0.46% | Nov 12, 2026 |
| David Weill | Director | 16,392 | 0.05% | Sep 14, 2026 |
| Thomas J. Gunderson | Director | 16,642 | 0.05% | Jun 17, 2026 |
| Edward M. Basile | Director | 5,788 | 0.02% | May 22, 2026 |
| Stephanie Lovell | Director | 5,788 | 0.02% | May 22, 2026 |
| Edwin Kania | Director | 309,874 | 0.89% | May 22, 2026 |
| Merilee Raines | Director | 6,981 | 0.02% | May 22, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| James R. Tobin Director | Nov 9, 2026 | Sale | −4,000 | $94.98 | $379.92K | 2,922 |
| James R. Tobin Director | Nov 9, 2026 | Sale | −59 | $93.96 | $5.54K | 6,922 |
| Fernando N. Araujo See Remarks | Oct 28, 2026 | Award | +22,969 | – | – | 22,969 |
| David Weill Director | Sep 11, 2026 | Buy | +1,336 | $81.63 | $109.06K | 16,392 |
| James R. Tobin Director | Aug 17, 2026 | Gift | −18,000 | – | – | 0 |
| Waleed H. Hassanein President & CEO, Director | Jul 10, 2026 | Award | +49,669 | – | – | 171,093 |
| Nicholas Corcoran See remarks | Jul 10, 2026 | Award | +11,727 | – | – | 41,558 |
| Gerardo Hernandez Chief Financial Officer | Jul 10, 2026 | Award | +17,246 | – | – | 31,935 |
| Thomas J. Gunderson Director | Jun 15, 2026 | Sale | −9,624 | $75.06 | $722.38K | 16,642 |
| Thomas J. Gunderson Director | Jun 15, 2026 | Option exercise | +19,285 | $2.21 | $42.62K | 26,266 |
| David Weill Director | May 20, 2026 | Award | +2,922 | – | – | 15,056 |
| Edwin Kania Director | May 20, 2026 | Award | +2,922 | – | – | 263,732 |
| Thomas J. Gunderson Director | May 20, 2026 | Award | +2,922 | – | – | 6,981 |
| Edward M. Basile Director | May 20, 2026 | Award | +2,922 | – | – | 5,788 |
| Stephanie Lovell Director | May 20, 2026 | Award | +2,922 | – | – | 5,788 |
| James R. Tobin Director | May 20, 2026 | Award | +2,922 | – | – | 6,981 |
| Merilee Raines Director | May 20, 2026 | Award | +2,922 | – | – | 6,981 |
| Matthew S. Forsyth See Remarks | May 19, 2026 | Award | +15,409 | – | – | 15,409 |
| Stephanie Lovell Director | Mar 4, 2026 | Sale | −1,193 | $149.62 | $178.50K | 2,866 |
| David Weill Director | Mar 4, 2026 | Option exercise | +3,571 | $14.20 | $50.71K | 15,705 |
| David Weill Director | Mar 4, 2026 | Sale | −3,571 | $146.82 | $524.29K | 12,134 |
| Gerardo Hernandez Chief Financial Officer | Mar 4, 2026 | Sale | −5,912 | $147.21 | $870.31K | 14,689 |
| Gerardo Hernandez Chief Financial Officer | Mar 4, 2026 | Option exercise | +5,912 | $69.84 | $412.89K | 20,601 |
| Gerardo Hernandez Chief Financial Officer | Mar 4, 2026 | Sale | −1,324 | $147.21 | $194.91K | 14,689 |
| Gerardo Hernandez Chief Financial Officer | Mar 4, 2026 | Option exercise | +1,324 | $77.12 | $102.11K | 16,013 |
| Anil P. Ranganath See remarks | Mar 2, 2026 | Sale | −864 | $139.12 | $120.20K | 13,091 |
| Nicholas Corcoran See remarks | Mar 2, 2026 | Sale | −2,966 | $139.12 | $412.63K | 29,831 |
| Gerardo Hernandez Chief Financial Officer | Mar 2, 2026 | Sale | −375 | $139.12 | $52.17K | 14,689 |
| Giovanni Cecere Chief Commercial Officer | Feb 18, 2026 | Award | +11,082 | – | – | 19,057 |
| Nicholas Corcoran See remarks | Jan 23, 2026 | Tax withholding | −984 | $135.30 | $133.14K | 32,797 |
| Gerardo Hernandez Chief Financial Officer | Dec 4, 2025 | Sale | −920 | $139.62 | $128.45K | 15,064 |
| David Weill Director | Dec 3, 2025 | Sale | −5,000 | $138.64 | $693.20K | 12,134 |
| David Weill Director | Dec 3, 2025 | Option exercise | +5,000 | $14.20 | $71.00K | 17,134 |
| Anil P. Ranganath See remarks | Nov 25, 2025 | Option exercise | +3,000 | $93.88 | $281.64K | 16,955 |
| Anil P. Ranganath See remarks | Nov 25, 2025 | Sale | −3,000 | $145.22 | $435.66K | 13,955 |
| Waleed H. Hassanein President & CEO, Director | Nov 17, 2025 | Buy | +8,775 | $114.00 | $1.00M | 495,009 |
| Edward M. Basile Director | Oct 29, 2025 | Sale(10b5-1 plan) | −4,142 | $130.45 | $540.32K | 2,866 |
| Edward M. Basile Director | Oct 29, 2025 | Option exercise | +4,142 | $0.70 | $2.90K | 7,008 |
| Waleed H. Hassanein President & CEO, Director | Aug 7, 2025 | Buy | +6,617 | $116.08 | $768.10K | 484,376 |
| Waleed H. Hassanein President & CEO, Director | Aug 7, 2025 | Buy | +1,858 | $116.85 | $217.11K | 486,234 |
| Waleed H. Hassanein President & CEO, Director | Aug 6, 2025 | Buy | +8,400 | $118.68 | $996.91K | 477,759 |
| Edward M. Basile Director | Aug 4, 2025 | Sale(10b5-1 plan) | −4,143 | $125.51 | $519.99K | 2,866 |
| Edward M. Basile Director | Aug 4, 2025 | Option exercise | +4,143 | $0.70 | $2.90K | 7,009 |
| Anil P. Ranganath See remarks | Jun 9, 2025 | Sale | −686 | $139.80 | $95.90K | 13,955 |
| Edward M. Basile Director | May 27, 2025 | Sale(10b5-1 plan) | −5,000 | $126.45 | $632.25K | 2,866 |
| Edward M. Basile Director | May 27, 2025 | Option exercise | +5,000 | $0.70 | $3.50K | 7,866 |
| David Weill Director | May 23, 2025 | Sale | −732 | $123.88 | $90.68K | 12,134 |
| Edwin Kania Director | May 22, 2025 | Award | +2,134 | – | – | 260,810 |
| Merilee Raines Director | May 22, 2025 | Award | +2,134 | – | – | 4,059 |
| Edward M. Basile Director | May 22, 2025 | Award | +2,134 | – | – | 2,866 |
| James R. Tobin Director | May 22, 2025 | Award | +2,134 | – | – | 4,059 |
| David Weill Director | May 22, 2025 | Award | +2,134 | – | – | 12,866 |
| Stephanie Lovell Director | May 22, 2025 | Award | +2,134 | – | – | 4,059 |
| Thomas J. Gunderson Director | May 22, 2025 | Award | +2,134 | – | – | 4,059 |
| Edward M. Basile Director | May 9, 2025 | Sale(10b5-1 plan) | −6,000 | $115.63 | $693.78K | 732 |
| Edward M. Basile Director | May 9, 2025 | Option exercise | +6,000 | $0.70 | $4.20K | 6,732 |
| Tamer I. Khayal Chief Commercial Officer | Mar 3, 2025 | Sale | −2,407 | $76.43 | $183.97K | 36,042 |
| Waleed H. Hassanein President & CEO, Director | Feb 25, 2025 | Award | +59,781 | – | – | 121,424 |
| Anil P. Ranganath See remarks | Feb 24, 2025 | Award | +5,634 | – | – | 14,641 |
| Tamer I. Khayal Chief Commercial Officer | Feb 24, 2025 | Award | +17,606 | – | – | 38,449 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of TransMedics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 291,098 shares on Sep 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| James R. Tobin Director | Nov 9, 2026 | 4,059 | $385.47K | Nov 9, 2026 | Restricted Stock |
| Thomas J. Gunderson Director | Jun 15, 2026 | 9,624 | $722.40K | Jun 15, 2026 | Stock Option Exercise |
| Gerardo Hernandez Officer | Mar 4, 2026 | 7,236 | $1.07M | Mar 4, 2026 | Stock Option Exercise |
| Stephanie Lovell Director | Mar 4, 2026 | 1,193 | $178.49K | Mar 4, 2026 | Restricted Stock |
| David Weill Director | Mar 4, 2026 | 3,571 | $524.29K | Mar 4, 2026 | Stock Option Exercise |
| David Weill Director | Dec 3, 2025 | 5,000 | $693.21K | Dec 3, 2025 | Stock Option Exercise |
| Anil P. Ranganath Officer | Nov 25, 2025 | 3,000 | $435.67K | Nov 25, 2025 | Stock Option Exercise |
| Edward M. Basile Director | Oct 29, 2025 | 4,142 | $540.32K | Oct 29, 2025 | Stock Option Exercise |
| Edward M. Basile Director | Aug 4, 2025 | 4,143 | $519.99K | Aug 4, 2025 | Stock Option Exercise |
| Edward M. Basile Director | May 27, 2025 | 5,000 | $632.25K | May 27, 2025 | Stock Option Exercise |
| David Weill Director | May 23, 2025 | 732 | $90.68K | May 23, 2025 | Restricted Stock |
| Edward M. Basile Director | May 9, 2025 | 6,000 | $693.78K | May 9, 2025 | Stock Option Exercise |
| Stephen Gordon Officer | Mar 4, 2025 | 5,942 | $389.85K | Mar 4, 2025 | RSU |
| Edward M. Basile Director | Nov 5, 2024 | 6,750 | $564.01K | Nov 5, 2024 | Stock Option Exercise |
| Tamer I. Khayal Officer | Nov 1, 2024 | 7,625 | $625.02K | Nov 1, 2024 | Stock Option Exercise |
See a number that looks wrong?